Back to Browse Journals » Cancer Management and Research » Volume 4

The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses

Authors Coventry BJ, Ashdown ML

Published Date August 2012 Volume 2012:4 Pages 215—221


Received 18 May 2012, Accepted 7 July 2012, Published 2 August 2012

Brendon J Coventry, Martin L Ashdown

Discipline of Surgery, University of Adelaide, Royal Adelaide Hospital and Faculty of Medicine, University of Melbourne, Australia

Background: This year marks the twentieth anniversary of the approval by the US Food and Drug Administration of interleukin-2 (IL2) for use in cancer therapy, initially for renal cell carcinoma and later for melanoma. IL2 therapy for cancer has stood the test of time, with continued widespread use in Europe, parts of Asia, and the US. Clinical complete responses are variably reported at 5%–20% for advanced malignant melanoma and renal cell carcinoma, with strong durable responses and sustained long-term 5–10-year survival being typical if complete responses are generated.
Methods: The literature was reviewed for the actions and clinical effects of IL2 on subsets of T cells. The influence of IL2 on clinical efficacy was also sought.
Results: The review revealed that IL2 is capable of stimulating different populations of T cells in humans to induce either T effector or T regulatory responses. This apparent "functional paradox" has confounded a clear understanding of the mechanisms behind the clinical effects that are observed during and following administration of IL2 therapy. An average complete response rate of around 7% in small and large clinical trials using IL2 for advanced renal cell carcinoma and malignant melanoma has been shown from a recent review of the literature.
Conclusion: This review considers the published literature concerning the actions and emerging clinical effects of IL2 therapy, spanning its 20-year period in clinical use. It further details some of the recently described "bimodal" effects of IL2 to explain the apparent functional paradox, and how IL2 might be harnessed to emerge rapidly as a much more effective and predictable clinical agent in the near future.

Keywords: interleukin-2, cancer therapy, immunotherapy, immune response, translational research, cytokines, regulatory T cells, immune modulation, complete responses, bimodal role

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Other articles by this author:

Readers of this article also read:

Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery

Sugimoto K, Shimizu N, Oki T, Nose K, Nishioka T, Adomi S, Ohzeki T, Esa A, Uemura H

Cancer Management and Research 2013, 5:85-89

Published Date: 24 May 2013

Optimal management of renal cell carcinoma in the elderly: a review

Quivy A, Daste A, Harbaoui A, Duc S, Bernhard JC, Gross-Goupil M, Ravaud A

Clinical Interventions in Aging 2013, 8:433-442

Published Date: 19 April 2013

Ocular argyrosis secondary to long-term ingestion of silver nitrate salts

Stafeeva K, Erlanger M, Velez-Montoya R, Olson JL

Clinical Ophthalmology 2012, 6:2033-2036

Published Date: 5 December 2012

Characterization of the inflammatory response to four commercial bone graft substitutes using a murine biocompatibility model

Markel DC, Guthrie ST, Wu B, Song Z, Wooley PH

Journal of Inflammation Research 2012, 5:13-18

Published Date: 18 January 2012

Fe3O4/Au magnetic nanoparticle amplification strategies for ultrasensitive electrochemical immunoassay of alfa-fetoprotein

Gan N, Jin H, Li T, Zheng L

International Journal of Nanomedicine 2011, 6:3259-3269

Published Date: 9 December 2011

Diagnostic indicators for peptic ulcer perforation at a tertiary care hospital in Thailand

Suriya C, Kasatpibal N, Kunaviktikul W, Kayee T

Clinical and Experimental Gastroenterology 2011, 4:283-289

Published Date: 9 December 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009